An MRNA Vaccine Against SARS-CoV-2 – Preliminary Report

This looks like great news, but I have zero medical knowledge, so I'm still left scratching my head. Rather than read what doctors have to say about these results, I instead decided to see what these results did to Moderna's stock price. Including the after-hours pricing, it looks to be up a whopping 40%! Looks like Wall Street is convinced that most of us will be willing to roll up our sleeves in 2021.

> Before vaccination, no participant had detectable 80% live-virus neutralization at the highest serum concentration tested (1:8 dilution) in the PRNT assay. At day 43, wild-type virus–neutralizing activity capable of reducing SARS-CoV-2 infectivity by 80% or more (PRNT80) was detected in all participants, with geometric mean PRNT80 responses of 339.7 (95% CI, 184.0 to 627.1) in the 25-μg group and 654.3 (95% CI, 460.1 to 930.5) in the 100-μg group ().

This does really sound good.